Neopterin plasma concentrations in patients with aneurysmal subarachnoid hemorrhage: Correlation with infection and long-term outcome by Azurmendi, L et al.
J Neurosurg  Volume 124 • May 2016 1287
cliNical article
J Neurosurg 124:1287–1299, 2016
AneurysmAl subarachnoid hemorrhage (aSAH) is a subtype of stroke associated with high rates of mortality and morbidity. Fifteen percent of patients 
die before arriving at a hospital, and 25% of deaths occur 
within the first 24 hours.34 Among the survivors, 30% will 
develop a long-term delayed neurological deficit that will 
affect their quality of life.21,32
The long-term outcome partially depends on early di-
agnosis and management.1,12 Therefore, if an aneurysm is 
detected by CT in a patient with aSAH, invasive treatment 
is indicated to prevent a second hemorrhage from the af-
fected vessel, the most important cause of death in the first 
24 hours following aSAH.20,25 Large studies, such as the 
International Subarachnoid Aneurysm Trial (ISAT), have 
investigated whether neurosurgical clipping or endovas-
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shown, however, that the outcome depends mainly on un-
modifiable factors present at admission and on secondary 
complications rather than the choice of treatment.3,20,25
Until recently, the most accepted criteria for predicting 
the outcome of aSAH have been increased age and results 
of clinical and radiological assessment scales for evalua-
tion of the patient’s neurological state at hospital admis-
sion, such as the Fisher grade, which measures the severity 
of the hemorrhage,17 and the World Federation of Neuro-
surgical Societies (WFNS) scale, which uses the Glasgow 
Coma Scale (GCS) and assessment of focal neurological 
deficits to establish the severity of symptoms.14,17,28 
Interest in the measurement of CSF and blood bio-
markers has increased in the last few years because the 
ability to monitor patients throughout hospitalization may 
lead to important improvements in their management. In-
creased concentrations of S100 calcium binding protein–
b (S100b), C-reactive protein, adhesion and matrix mole-
cules, and vasogenic and cardiac markers have been found 
in aSAH patients with poor outcomes, but the limited ac-
curacy of most of these markers has hampered their use in 
clinical practice.13,27,36,38
Neopterin, a catabolic product of GTP (guanosine-5-tri-
phosphate) produced by human monocytes-macrophages 
upon stimulation with interferon-g, has been reported as 
an outcome and infection biomarker for several inflam-
matory diseases.6,19,35 Moreover, Mathiesen et al. showed 
that the CSF and plasma concentrations of neopterin were 
higher in patients suffering from aSAH than in controls. 
The use of neopterin to predict patient outcomes was also 
studied, but no association was found.23
We hypothesized that inflammation and infection af-
ter the hemorrhagic event have important effects on out-
come,11 and we evaluated neopterin as a biomarker of in-
flammation and infection that may be useful in predicting 
outcomes in aSAH patients.
methods
patients and sample collection
The aSAH patients included in the present study were 
hospitalized at the Pitié-Salpêtrière Hospital of Paris 
(France) between July 2004 and April 2008. Aneurysmal 
SAH was confirmed angiographically and by CT. The 
study was approved by the local ethics committee (Co-
mité de Protection des Personnes, Pitié-Salpêtrière, Paris, 
France). All patients or their surrogates signed a written 
informed consent.
Patient neurological status was evaluated on admission 
to the intensive care unit by use of the WFNS scale. De-
pending on the location and the size of the aneurysm, the 
aneurysm was not treated, was treated by surgical clip-
ping, or was treated by endovascular coil embolization. 
More details on the clinical monitoring and treatment 
have been previously described by Turck et al.36
Among 198 consecutively hospitalized patients, 137 
were excluded from the present study due to 1) presence 
of more than 1 hemorrhagic event, 2) admission to the hos-
pital more than 48 hours after the onset of symptoms, 3) 
missing clinical information, or 4) insufficient sample vol-
ume to perform our assays. Sixty-one patients were then 
finally included in this study (Fig. 1).
Plasma samples were collected the day of arrival at the 
hospital and subsequently every day for 10 consecutive 
days (Day 1–Day 10).
The Glasgow Outcome Scale (GOS) was used to assess 
patient outcomes by telephone interview 12 months after 
the hemorrhagic event. Depending on the grade of depen-
dence, the outcome was classified as poor (GOS score 1, 2, 
or 3) or good (GOS score 4 or 5) by a doctor who had not 
participated in the initial care.
During hospitalization, patient infection status was de-
fined daily based on the criteria established by the Interna-
Fig. 1. Inclusion criteria flowchart for the population investigated in this study.
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tional Sepsis Forum Consensus Conference on Definitions 
of Infection in the Intensive Care Unit.4 When there was 
a suspicion of infection based on systematic clinical and 
biological criteria, bacteriological samples were obtained. 
Antibiotic therapy was started as soon as there was suspi-
cion of infection and was readjusted once the results of the 
cultures were obtained. The first day of antibiotic therapy 
in infected patients was designated as T-0, the day before 
treatment as T-1, and 2 days before treatment as T-2.
Neopterin and s100β assays
Neopterin concentrations in plasma samples were mea-
sured using a commercially available enzyme-linked im-
munosorbent assay (ELISA) kit according to the manufac-
turer’s instructions (BRAHMS GmbH).
S100b concentrations were determined with an immu-
noluminometric sandwich assay on an LIA-mat 300 ana-
lyzer (Byk-Sangtek France Laboratories) using manufac-
turer’s reagents.2 Technical variability was assessed using 
internal quality controls (coefficient of variation ≤ 20%).
Concentrations of both molecules were measured once 
per day during the first 10 days of hospitalization in order 
to evaluate their capacity to act as outcome and infection 
markers. 
statistical analysis
Statistical analyses were performed with SPSS soft-
ware (version 21, SPSS Inc.). The Shapiro-Wilk test was 
used to test deviations from Gaussian distribution of age, 
neopterin concentration, and S100b concentration. Age 
was normally distributed, and a parametric test was per-
formed to compare the differences between the ages of pa-
tients with good versus poor outcome. Because neopterin 
and S100b concentrations did not follow a normal distri-
bution, the Mann-Whitney U-test was used for statistical 
comparisons between 2 unpaired groups and the Fried-
man test for comparisons of paired groups. Fisher’s exact 
test and the chi-square test were used to assess whether 
the groups of patients with good or poor outcome differed 
significantly with respect to sex, WFNS grade, modified 
Fisher scale grade, presence of convulsions, use of exter-
nal ventricular drain (EVD), presence of hydrocephalus, 
and treatment. Univariate and multivariate analyses were 
performed to assess the association between variables. In 
a first analysis, the 12-month GOS score was set as the 
dependent variable and the WFNS grade, S100b concen-
tration, neopterin concentration, and presence of infection 
as confounders. In a second analysis, the presence/absence 
of infection was set as the dependent variable and sex, 
WFNS grade, blood white blood cell (WBC) count, neop-
terin concentration, and EVD use were set as confounders. 
The model was validated using the bootstrap method. Cat-
egorical data were dichotomized according to the crite-
ria of the demographic characteristics table. Longitudinal 
data were also dichotomized according to the best cutoff 
obtained from area under the receiver operating character-
istic (ROC) curve (AUC) analysis. 
All statistical tests were bilateral, and a p value < 0.05 
was considered statistically significant. When multiple 
comparisons were done, Bonferroni correction of the p 
values was applied. Sample size estimation was calculated 
to obtain a power of 90% and a 2-sided error of 5%.30
Receiver operating characteristic curves were calcu-
lated for WFNS grade at Day 1 and for neopterin and 
S100b concentrations from Day 1 to Day 10. AUC values, 
specificity, sensitivity, and 95% CIs were calculated with 
the pROC package for S+, version 8.1. (TIBCO Software 
Inc.).30 A cutoff value corresponding to the best combi-
nation of specificity and sensitivity was obtained at each 
time point for both markers. The Youden index (J) was 
obtained using the following formula: J = (SE% + SP%) - 
100, where SE is sensitivity and SP is specificity. 
results
demographic characteristics
The demographic characteristics of the 61 patients in-
cluded in this study are summarized in Table 1. Most of 
the patients were women (64%), and the patients’ mean 
age (± SD) was 52.8 ± 11.8 years. In this cohort, 61% of the 
patients had no motor deficit at admission to the hospital 
(WFNS grade 1 or 2), and 75% were treated with emboli-
zation. Angiographic vasospasm developed in 38% of the 
patients and infection in 69%.
Prediction of Outcome According to Neopterin and S100β 
plasma concentrations
At 12 months after hospital admission there were no 
significant differences between patients with good and 
those with poor outcomes with respect to the modified 
Fisher scale grade or the development of delayed cerebral 
ischemia (DCI), seizures (data not shown), or angiograph-
ic vasospasm. Nevertheless, univariate analyses showed 
that even though our study group of patients with aSAH 
included more women than men, the number of men who 
had a poor outcome (n = 12, 54.5%) was greater than the 
number of women (n = 10, 45.5%). WFNS grade and GCS 
score were highly associated with poor outcome at 12 
months (p < 0.0001). Furthermore, the intervention tech-
nique (clipping or coiling) appeared to play an important 
role in the long-term outcome, as all the patients whose 
aneurysms were not treated had a poor outcome at 12 
months (p = 0.005). Finally, most of the patients with a 
poor outcome after hospitalization (21 of 22) developed an 
infection during hospitalization, which strengthened the 
association between outcome and the presence of infec-
tion (p = 0.007, OR 18).
To evaluate the utility of neopterin and S100b for pre-
dicting 12-month outcome after aSAH, the concentrations 
were measured every day. Patients were classified accord-
ing to poor (GOS score 1, 2, or 3) or good (GOS score 4 
or 5) outcome at 12 months. Results are shown in Fig. 2. 
Patients with poor outcomes showed significantly higher 
plasma concentrations of neopterin and S100b than pa-
tients with good outcome. The S100b concentrations were 
elevated from the day of hospital admission and remained 
elevated during the whole period of measurement, where-
as significantly higher concentrations of neopterin were 
found from 3 days after hospitalization (Day 3) onward. 
Moreover, in the case of neopterin, a progressive increase 
in concentrations was observed.
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To evaluate the performance of these 2 variables for the 
prediction of patient outcomes, ROC curves were used. 
Detailed results are shown in Table 2 and Figs. 3 and 4. 
For neopterin, the best discrimination was found 5 days 
after hospitalization: AUC 84.2% (95% CI 71.9%–94.1%) 
for a cutoff concentration of 12.7 nmol/L, with specific-
ity and sensitivity values of 74.4% and 86.4%, respec-
tively (J = 60.8). For S100b, the best discrimination was 
found 10 days after hospitalization: AUC 86.9% (95% CI 
73.5%–97.3%) for a cutoff concentration of 0.2 μg/L, with 
specificity and sensitivity values of 86.4% and 88.2%, re-
spectively.
Taking into account the best cutoff values obtained 
from the ROC analysis (AUC), we dichotomized the longi-
tudinal variables in univariate and multivariate regression 
analyses. Univariate analysis showed that sex, presence of 
infection, and WFNS grade, as well as the concentrations 
of neopterin and S100b, were associated with outcome at 
12 months. In multivariate analysis, however, only neop-
terin concentration and WFNS grade displayed a relation-
ship with the patients’ long-term status (Table 3).
The combination of WFNS grade at admission to the 
hospital—AUC 89% (95% CI 81.3%–96.7%), specificity 
87.2% and sensitivity 77.3% (J = 64.5)—and neopterin 
concentration at Day 5 dramatically improved the overall 
accuracy of outcome prediction, reaching a Youden index 
(J) of 75.5. 
infection prediction according to plasma Neopterin 
concentration and wbc count
Infection in aSAH patients can produce systemic in-
flammatory response syndrome, with associated elevated 
body temperature, elevated heart rate, tachypnea, and leu-
kocytoses. Because these symptoms appeared to be im-
portant factors affecting prognosis after aSAH (p = 0.001), 
we evaluated whether WBC counts and neopterin concen-
trations were significantly different in patients with (n = 
42) and without infection (n = 19).
We first evaluated the capacity of these variables to 
help us decide whether or not antibiotic therapy should be 
initiated. We found that the concentrations of neopterin 
obtained on the first day of antibiotic treatment for patients 
who developed an infection were significantly greater than 
concentrations obtained at the corresponding time point 
TABLE 1. Comparison of demographic and clinical characteristics of 61 aSAH patients stratified by outcome at 12 
months*
 Outcome at 12 Mos
Characteristic Total (n = 61) Good (n = 39) Poor (n = 22) p Value†
Sex  0.03
  Male 22 (36.1%) 10 (25.6%) 12 (54.5%)  
  Female 39 (63.9%) 29 (74.4%) 10 (45.5%)  
Age in yrs  0.875‡
  Mean (SD) 52.8 (11.8) 52.3 (12.5) 53.8 (10.5)  
WFNS grade  <0.0001
  1 or 2 37 (60.7%) 32 (82.1%) 5 (22.7%)  
  3, 4, or 5 24 (39.3%) 7 (17.9%) 17 (77.3%)  
GCS score   <0.0001
  <9 15 (24.6%) 2 (5.1%) 13 (59.1%)  
 9–12 7 (11.5%) 3 (7.7%) 4 (18.2%)  
  ≥13 39 (63.9%) 34 (87.2%) 5 (22.7%)  
Vasospasm  0.871
  Yes 23 (37.7%) 15 (38.5%) 8 (36.4%)  
  No 38 (62.3%) 24 (61.51%) 14 (63.6%)  
Treatment   0.005
  Surgery 11 (18%) 5 (12.8%) 6 (27.3%)  
  Embolization 46 (75.4%) 34 (87.2%) 12 (54.5%)  
  No treatment 4 (6.6%) 0 (0%) 4 (18.2%)  
EVD   <0.0001
  Yes 37 (60.6%) 16 (41 %) 21 (95.5%)  
  No 24 (39.4%) 23 (59%) 1 (4.5%)  
Infection  <0.0001
  Yes 42 (68.9%) 21 (53.8%) 21 (95.5%)  
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in those who did not develop an infection (see Discussion) 
(Fig. 5). The Youden index performance, used to differen-
tiate between these 2 groups, reached a value of J = 39.59. 
In contrast, the WBC count did not differ significantly be-
tween the 2 groups (see Table 5 and Fig. 6).
Because neopterin concentration appeared to be an 
efficient biomarker for infection, we evaluated its perfor-
mance throughout the entire hospitalization. Neopterin 
concentrations were significantly higher in infected pa-
tients from 3 days after hospitalization onward up to 10 
days (Fig. 7). The performance of this biomarker in es-
tablishing this differentiation was most effective at Day 
3 (AUC 76.7%), which corresponded in most of the cases 
with 2 days before the start of infection treatment (Table 
5 and Fig. 8).
To evaluate whether this increase in neopterin con-
centrations in infected patients was correlated with the 
appearance of infection, univariate analyses were per-
formed using values obtained at Day 5, which represented 
the mean day of infection detection (i.e., the mean of the 
numbers of days of hospitalization at which infection was 
detected). Univariate analysis demonstrated that there 
was a relationship between the presence of an infection 
and high concentrations of neopterin, poor neurological 
state at admission to the hospital, and the placement of an 
EVD. There was, however, no relation between the WBC 
count and the development of infection. When we tested 
the same parameters in multivariate analyses, neopterin 
remained an independent factor for the presence of infec-
tion in aSAH patients (Table 4).
discussion
Long-term outcome after aSAH is a major clinical is-
sue, and the rates of mortality and morbidity are high.31 
The prediction of 12-month outcome as well as the detec-
tion of complications during the hospitalization may help 
physicians to provide better care for aSAH patients and 
better inform family members of what to expect during 
the months to come.15 
Several unmodifiable factors, such as increased age or 
the level of consciousness of the patient at hospital admis-
sion, have been proposed and used as the best univariate 
predictors of outcome.17 Among these, we found that the 
level of consciousness (GCS score) and focal neurological 
deficit (WFNS score) were the strongest predictors (p < 
0.001). However, the failure of these neurological assess-
ment scales to address complications occurring during 
hospitalization has highlighted the need for blood bio-
marker identification.
The calcium-binding protein S100b has been one of 
the most commonly used prognostic biomarkers in vari-
ous conditions associated with brain damage, such as trau-
matic brain injury, stroke, and aSAH.27 However, the use 
of this biomarker in clinical practice has been impeded 
by limitations in its sensitivity and specificity. Mathiesen 
et al. evaluated the capacity of neopterin to act as a bio-
marker for outcome prediction in aSAH patients, but no 
association was found between neopterin concentrations 
and patient outcomes.23 In the present study, however, we 
found that increased concentrations of neopterin predicted 
poor outcome at 12 months in 61 patients followed for 10 
days after aSAH. Although the concentrations of neop-
terin followed the same kinetics in both studies, the low 
number of patients included in the prior analysis may have 
been the cause of this difference in outcome determina-
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tion. The performance of neopterin in differentiating be-
tween patients with good and poor outcomes is quite simi-
lar to that of S100b or WFNS. Nevertheless, the combina-
tion of neopterin with WFNS data substantially increases 
the total values for sensitivity and specificity, reaching a 
Youden index value (J) of 75.5. This fact highlights the 
finding that although the impact of initial hemorrhage is a 
key factor affecting outcome, monitoring the patient dur-
ing the acute phase is also important for improving the 
patient’s outcome.
There are 2 major advantages of neopterin over already 
established prognostic methods. First, neopterin is an ear-
lier biomarker than S100b, making it possible to identi-
fy, only 5 days after hospitalization, patients who are at 
higher risk of inflammatory complications. This allows 
the application of treatment before complications appear, 
increasing the level of care and consequently decreasing 
the long-term deterioration risk.
The second advantage is that neopterin can function as 
a biomarker for complications such as infection or DCI 
that are not addressed by the currently used clinical scales. 
These events must be considered during the process of 
biomarker discovery in aSAH, because they appear to be 
the main causes of pathophysiological worsening.
After the hemorrhagic event, the blood clot in the sub-
arachnoid space leads to recruitment of adhesion mol-
ecules at the surface of endothelial cells.5,22,24,29 Immuno-
logical cells such as neutrophils and macrophages phago-
cytize the red blood cells and degranulate between 2 and 4 
days after activation, releasing a large quantity of intracel-
lular endothelins and reactive oxygen species (ROS).26 The 
release of ROS causes a decrease in vasodilatation, lead-
ing to cerebral vasoconstriction and the development of 
angiographic vasospasm and DCI.37 Because vasospasm 
and DCI are associated with important adverse effects 
on quality of life, many studies have been conducted to 
investigate their underlying mechanisms. However, other 
inflammatory events that play important roles in the long-
Fig. 3. ROC curves for neopterin representing the ability to differentiate between patients with poor and those with good outcomes 
from the day of hospital admission (Day 1 [D1]) through the 10th day of hospitalization. 
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Fig. 4. ROC curves for S100b representing the ability to differentiate between poor and good outcome patients from the day of 
hospital admission (Day 1 [D1]) through the 10th day of hospitalization. 
table 3. univariate and multivariate analysis of different factors 
for predicting outcome at 12 months after asah*
Analysis & Factor p Value OR (95% CI)
Univariate analysis
  Sex 0.027 0.287 (0.09–0.87)
  WFNS grade <0.0001 15.54 (4.28–56.44)
  S100β (<0.4 µg/L) 0.026 3.71 (1.17–11.8)
  Neopterin (12.7 nmol/L) <0.0001 18.37 (4.46–75.52)
  Infection 0.007 17.8 (2.2–142.7)
Multivariate analysis
  WFNS grade 0.001 12.91 (2.79–59.68)





table 4. univariate and multivariate analysis of different factors 
for predicting the presence of infection*
Analysis & Factor p Value OR (95% CI)
Univariate analysis   
  Sex 0.29 0.53 (0.16–1.73)
  WFNS grade 0.004 21.8 (2.66–178.53)
  WBC (10.9 × 106 cells/mm) 0.18 2.75 (0.63–12.1)
  Neopterin (12.7 nmol/L) 0.002 8.66 (2.17–34.49)
  EVD <0.0001 13.75 (3.65–51.81)
Multivariate analysis
  WFNS grade 0.099 6.88 (0.69–68.29)
  Neopterin (12.7 nmol/L) 0.03 5.63 (1.13–28.06)
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term condition of aSAH patients, such as infections, have 
not been adequately investigated.8,10
In our study, we focused our attention on infection be-
cause infections developed during hospitalization in 95% 
of the patients with poor outcomes,10 indicating that early 
detection and treatment of bacterial infections may im-
prove patient outcomes. In addition, the discrimination of 
infection from other pathologies with similar presentations 
should decrease the amount of unnecessary antibiotic use, 
avoiding associated resistance, toxicity, and allergic reac-
tions.16,33 
The WBC count is used as a reference value to detect 
several inflammatory diseases. However, in aSAH patients 
the WBC count cannot be used for this purpose because of 
the leukocytosis produced by the blood clot. To our knowl-
edge, this is the first reported study showing that a marker 
of inflammation able to predict long-term outcome after 
aSAH is also correlated with the appearance of infection. 
Neopterin concentrations, which indicated overexpression 
of this biomarker in all 61 patients included in this study, 
enabled us to significantly differentiate between patients 
who developed an infection after aSAH and patients who 
did not. When comparing the concentrations before the 
detection of the infection, we found that concentrations of 
neopterin were already significantly different 2 days be-
fore the positive bacterial culture.
These results suggest that neopterin may be useful in 
clinical practice as a screening test to trigger earlier bac-
teriological studies. Based on our study results, the ideal 
day to measure neopterin concentrations seems to be 3 
days after admission to the hospital; this is approximately 
2 days before the detection of infection by bacterial cul-
ture. At this time point, we found that a cutoff value of 
11.8 nmol/L would allow correct classification in 77% of 
the cases with respect to whether infection will develop 
or not. However, several critical issues should be further 
evaluated regarding the use of this biomarker. The asso-
ciation between infection and outcome must be clarified to 
confirm that prevention of infection leads to improvement 
in patient outcomes. In addition, the exact time or sequen-
Fig. 8. ROC curves of neopterin representing the ability to differentiate between infected and uninfected patients from the admis-
sion to the hospital to 10 days after.
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tial times to measure the neopterin concentrations, as well 
as the best cutoff values to trigger initiation of treatment, 
must be defined. 
Thus far, we have not been able to confirm that neop-
terin is a direct diagnostic marker of infection or whether 
its concentrations in aSAH patients are associated with 
the initial hemorrhage, which would mean that a larger 
hemorrhage might increase the grade of inflammation, 
worsening the general state of the patient and consequent-
ly increasing the risk of infection. Alternatively, further 
pathophysiological insights may be obtained by measuring 
the concentrations of neopterin in patient CSF. As already 
mentioned by Mathiesen et al.,23 this polar molecule does 
not cross the blood-brain barrier, so the direct evaluation 
of the inflammation produced by the hemorrhage may in-
crease understanding of the relation between inflamma-
tion and infection development.23
Furthermore, in this cohort, the development of DCI 
and the amounts of blood measured by the Fisher scale 
were not correlated with outcome, findings which do not 
reflect the data in the literature.7,9,18
In summary, once these small confounders are elucidat-
ed, neopterin could become a useful biomarker to improve 
the clinical management and outcome in aSAH patients.
conclusions
Neopterin is a potential outcome and infection predic-
tor after aSAH. The objective information provided by the 
measurement of neopterin concentrations immediately af-
ter hospital admission and onward may enhance the per-
formance of other clinical methods for patient assessment. 
To evaluate the clinical utility of this biomarker, the results 
of the present study should be validated in larger and mul-
ticenter studies.
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